Related Experiment Video
Updated: Aug 8, 2025
03:23
Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis
Published on: May 10, 2024
843
Emerging therapies for eosinophilic esophagitis
Patrick D Meek1, Brian Hemstreet2
1Albany College of Pharmacy and Health Sciences, Albany, New York, USA.
Pharmacotherapy
|February 25, 2023
Summary
Eosinophilic esophagitis (EoE) is an esophageal inflammatory condition. New biologic therapies targeting specific cytokines show promise for managing EoE symptoms and disease progression when other treatments fail.
Area of Science:
- Gastroenterology
- Immunology
- Pharmacology
Background:
- Eosinophilic esophagitis (EoE) is an increasingly recognized esophageal inflammatory disorder.
- It is characterized by esophageal dysfunction and dysphagia, often triggered by antigen exposure.
- Current treatments like elimination diets, PPIs, and swallowed corticosteroids have limited efficacy for many patients.
Purpose of the Study:
- To review current and emerging therapeutic strategies for EoE.
- To highlight the role of targeted cytokine inhibition in EoE management.
- To discuss novel agents in clinical trials for EoE.
Main Methods:
- Review of current literature on EoE pathogenesis and treatment.
- Analysis of clinical trial data for novel EoE therapies.
- Focus on biologic agents targeting inflammatory pathways.
Main Results:
- Dupilumab, an IL-4 inhibitor, is approved and shows efficacy in EoE patients.
- Other IL-5 inhibitors (mepolizumab, reslizumab, benralizumab) are under investigation.
- Emerging therapies targeting Siglec-8, IL-13, and S1P receptors are in clinical trials.
Conclusions:
- Targeted biologic therapies represent a significant advancement in EoE treatment.
- These novel agents offer new hope for patients with refractory disease.
- Further research and clinical trials are crucial for optimizing EoE management.
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
375
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
375
01:21Barrett Esophagus-II: Clinical Manifestations and Management
246
Individuals with Barrett's esophagus are often asymptomatic, but they may experience symptoms commonly associated with GERD, such as heartburn and acid regurgitation. Additional symptoms can include difficulty swallowing, chest pain, unintentional weight loss, blood in the stool (which may appear black, tarry, or bloody), and episodes of vomiting.
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
246
01:19Antiasthma Drugs: Leukotriene Modifiers
394
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
394
01:29Gastroesophageal Reflux Disease II: Clinical Features and Management
132
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
132
01:26Peptic Ulcer Disease IV: Management
125
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
125
01:17Drugs for Treatment of Diarrhea-Predominant IBS
252
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
252